To read all of these articles and more, visit centerforbiosimilars.com.
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...
Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Pharmaceutical Technology on MSN9d
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...
A Matrix Global Advisors report highlights current barriers and recommendations for robust competition and patient savings in ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback